Physician profile
Supriya Gupta
NPI 1639588163
$2,847.47
in general payments reported to CMS, 2019-2025
23 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $923 · 2024: $915 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,847.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $684.93 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Inspire Medical Systems, INC. | $388.95 | 2023-2025 | Inspire |
| Exact Sciences Corporation | $358.68 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $353.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $295.94 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $136.64 | 2023-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $86.54 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $84.13 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Emd Serono, INC. | $63.24 | 2023-2025 | Serostim |
| Amgen INC. | $46.80 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.63 | 2023 | Jardiance |
| Viiv Healthcare Company | $33.09 | 2025 | Apretude |
| Gilead Sciences, INC. | $32.47 | 2023-2025 | |
| Glaxosmithkline, LLC. | $30.27 | 2024-2025 | Arexvy, Shingrix |
| Pfizer INC. | $28.18 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.91 | 2023-2024 | |
| Abiomed | $27.63 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $26.22 | 2025 | |
| Idorsia Pharmaceuticals US INC | $24.19 | 2023 | Quviviq |
| Ibsa Pharma INC. | $21.18 | 2025 | Tirosint, Licart, Flector |
| Janssen Pharmaceuticals, INC | $20.68 | 2024 | Invega Sustenna |
| Merck Sharp & Dohme LLC | $17.78 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Azurity Pharmaceuticals, INC. | $17.28 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.